Text Size

Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future

Levin, L .A.; Patrick, C.; Choudry, N.B.; Sharif, N.A.; Goldberg, J.L.


  • 2022
  • Front Neurol
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Clinical development

  • Affiliations

    Departments of Ophthalmology and Visual Sciences, Neurology & Neurosurgery, McGill University, Montreal, QC, Canada. TELUS Health, Ottawa, ON, Canada; Global Alliances and External Research, Ophthalmology Innovation Center, Santen Inc., Emeryville, CA, United States; Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, United States

Related Publications

STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%

Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators


Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022